USNA
NYSE · Consumer products
Usana Health Sciences Inc
$14.82
+0.45 (+3.13%)
Financial Highlights (FY 2026)
Revenue
907.36M
Net Income
10.55M
Gross Margin
78.3%
Profit Margin
1.2%
Rev Growth
-2.5%
D/E Ratio
0.03
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 78.3% | 78.3% | 33.9% | 33.9% |
| Operating Margin | 4.0% | 3.6% | 16.8% | 18.0% |
| Profit Margin | 1.2% | 1.1% | 16.2% | 16.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 907.36M | 930.72M | 119.49M | 111.86M |
| Gross Profit | 710.37M | 728.66M | 40.49M | 37.91M |
| Operating Income | 36.75M | 33.92M | 20.03M | 20.12M |
| Net Income | 10.55M | 9.74M | 19.36M | 18.26M |
| Gross Margin | 78.3% | 78.3% | 33.9% | 33.9% |
| Operating Margin | 4.0% | 3.6% | 16.8% | 18.0% |
| Profit Margin | 1.2% | 1.1% | 16.2% | 16.3% |
| Rev Growth | -2.5% | -2.5% | +14.6% | -0.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 3.46M | 3.46M | 100.99M | 110.95M |
| Total Equity | 131.51M | 131.51M | 246.01M | 260.40M |
| D/E Ratio | 0.03 | 0.03 | 0.41 | 0.43 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 68.64M | 66.89M | 31.27M | 29.25M |
| Free Cash Flow | — | — | 14.98M | 15.87M |